ATOSSA THERAPEUTICS, INC. - 10-Q Summary (Q2 2025)
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary medicines for breast cancer and other breast conditions. The company's lead drug candidate is oral (Z)-endoxifen, a Selective Estrogen Receptor Modulator (SERM). The company is currently in the research and development phase with no commercial product revenue.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(8.4) million | $(6.0) million | $(15.1) million | $(11.9) million |
| Operating Expenses | $9.0 million | $7.1 million | $16.5 million | $14.1 million |
| Cash & Equivalents (End of Period) | $57.9 million (as of June 30, 2025) | |||
| Working Capital | ||||
| Net Cash Used in Operating Activities | N/A | N/A | $(13.2) million | $(9.2) million |
| Accumulated Deficit | $226.9 million (as of June 30, 2025) |
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses increased by $1.9 million (27%) for the three months ended June 30, 2025, compared to the same period in 2024. This was driven primarily by a $1.6 million increase in clinical and non-clinical trial costs and a $0.2 million increase in R&D compensation.
- Higher Net Loss: The net loss for the three months ended June 30, 2025, increased to $8.4 million from $6.0 million in the prior year period, reflecting higher R&D spend and lower interest income.
- Decreased Interest Income: Interest income dropped to $0.6 million for Q2 2025 from $1.1 million in Q2 2024 due to lower average balances in money market accounts.
- Stock-Based Compensation: Stock-based compensation expense increased significantly to $0.8 million for Q2 2025 from $0.4 million in Q2 2024, largely due to new option grants.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes current cash resources ($57.9 million) are sufficient to fund operations for at least the next 12 months. However, the company expects to incur ongoing losses and will need to raise substantial additional capital in the future.
- Development Progress: The company received positive FDA feedback regarding a proposed dose optimization trial for (Z)-endoxifen in metastatic breast cancer, with a potential IND submission targeted for Q4 2025. The company is also advancing the EVANGELINE neoadjuvant trial and the I-SPY 2 EOP study.
- Nasdaq Compliance: The company received notice from Nasdaq on February 21, 2025, regarding non-compliance with the minimum closing bid price requirement ($1.00). The company has until August 20, 2025, to regain compliance.
- Intellectual Property Litigation: Intas Pharmaceuticals Ltd. filed Post Grant Review (PGR) and Inter Partes Review (IPR) petitions in April 2025 seeking to invalidate two of Atossa's patents related to (Z)-endoxifen. The company intends to vigorously contest these petitions.
- Australian Tax Contingency: The company recorded a $1.5 million liability related to uncertainty regarding the sustainability of its Australian R&D tax rebate position under audit.
Key Investor Verification Points
- Verify the timeline and regulatory status of the proposed IND submission for the metastatic breast cancer indication.
- Monitor the outcome of the Nasdaq compliance period ending August 20, 2025, and potential delisting risks.
- Track the progress of the PTAB decisions regarding the Intas Pharmaceuticals patent challenges (expected by September 8, 2025).
- Assess the company's ability to secure additional capital given the $13.2 million cash burn rate over the last six months.
- Review the status of the Australian R&D tax rebate audit and potential for additional liabilities beyond the recorded $1.5 million.